Cohen, Jonathan; Palumbo, Alison; Wing, Jason; Heinrich, Michael C. published an article in 2020, the title of the article was Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes.Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile And the article contains the following content:
Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the BCR-ABL1 fusion protein resulting from chromosomal translocation, most classically the 9;22 translocation. Tyrosine kinase inhibitors (TKIs) have been the standard of care since the FDA approval of imatinib in 2001. TKIs used to treat CML include nilotinib, dasatinib, bosutinib, and ponatinib. Using modern TKI-based therapy, the annual mortality and 10-yr survival rates for chronic phase CML are currently 1-2% and 80-90%, resp. Select patients receiving TKI-based therapies that have maintained a deep mol. response (DMR) may discontinue TKI therapy, with trial of treatment-free remission (TFR). This case series supports that TFR may be successfully achieved in patients receiving ponatinib. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
The Article related to ponatinib treatment free remission chronic myeloid leukemia mol response, Pharmacology: Drug Metabolism and other aspects.Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics